No Data
No Data
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Ocuphire Pharma Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Ocuphire Pharma, Lowers Price Target to $18
Express News | HC Wainwright & Co. Reiterates Buy on Ocuphire Pharma, Maintains $20 Price Target
Ocuphire Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1076.47% HC Wainwright & Co. → $20 Reiterates Buy → Buy 03/20/2024 1076.47% Alliance Global Par
Buy Rating Affirmed: Ocuphire Pharma's APX3330 Shows Promise for Diabetic Retinopathy and Pipeline Progress
Express News | Ocuphire Pharma Inc : Canaccord Genuity Cuts Target Price to $18 From $22
mohammad ahmady : y